Theravance (THRX) Misses Q2 EPS by 1c

Theravance (NASDAQ: THRX) reported Q2 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $10.7 million versus the consensus estimate of $10.9 million.

For earnings history and earnings-related data on Theravance (THRX) click here.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• Wipro (WIT) Tops Q1 EPS by 1c
• Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance